The event follows the platform's scientific community debut at the American Association for Cancer Research (AACR) Annual Meeting 2026 and its initial unveiling at Nasdaq MarketSite — and marks the first time the platform will be demonstrated live and without restriction to a global public audience of investors, researchers, and industry participants.

President and Chief Executive Officer Panna Sharma will lead the demonstration in real time — live, interactive, and unrehearsed — showing how withZeta.ai operates as a genuine AI co-scientist at the frontier of oncology drug discovery. Two identical sessions will be held to accommodate global time zones:

Morning Session: 8:30 AM ET — Register Here
Afternoon Session: 4:30 PM ET — Register Here
Each session will include a live platform walkthrough followed by an open Q&A with management.

From Scientific Validation to Public Stage

withZeta.ai made its scientific debut at AACR 2026 — one of the world's most rigorous forums for oncology and translational research — and was first unveiled at Nasdaq MarketSite, a globally recognized venue at the intersection of capital markets and innovation. April 30th represents a deliberate next step: opening the platform to the full public for the first time, with no gatekeeping, no curated excerpts, and no pre-recorded footage.

Attendees will watch in real time as the platform executes complex research workflows — synthesizing clinical, molecular, and scientific datasets simultaneously to generate insights and compress research timelines that historically required months of manual effort. This is not a product marketing event. It is a transparency event, and the platform will speak for itself.

A Platform Built for the Economics and Urgency of Rare Cancer

With the AI-driven drug discovery market projected to surpass $15 billion by 2030 and growing at over 30% annually, the industry is in the early stages of a structural transformation. Yet rare cancers remain the discipline's most persistent blind spot — historically neglected not for lack of scientific interest, but because the economics and timelines of traditional development make them commercially unattractive.

withZeta.ai was purpose-built to close that gap. The platform integrates:

A proprietary rare cancer ontology spanning hundreds of cancer subtypes, structuring biological knowledge in a form that AI agents can actively reason across — not merely retrieve.
Multi-database querying across clinical trial registries, biomedical literature, and molecular datasets — simultaneously and in real time, not sequentially.
Advanced generative AI models for molecular design, ADMET prediction, blood-brain barrier permeability analysis, and structure-activity relationship (SAR) evaluation — capabilities embedded in the platform's Ether0 generative chemistry architecture.
A scalable, subscription-based commercial model — with introductory, academic, and enterprise tiers — representing a non-dilutive, recurring revenue stream accessible to any researcher, institution, or biopharma organization globally.
Following its debut at Nasdaq MarketSite and AACR 2026, Lantern is advancing withZeta.ai as both a scientific accelerator and a commercial growth engine — one that creates value for rare cancer patients, for research institutions, and for Lantern shareholders simultaneously.

"The rarest cancers have always faced the longest waits — not because the science is absent, but because the infrastructure to move at the speed of urgency has never existed. withZeta.ai changes that. It is not a search engine, not a literature tool, and not a chatbot with oncology data loaded in. It is a multi-agentic AI-powered co-scientist, forged from years of real clinical development, careful curation of knowledge-bases and exquisite disease models. It is capable of executing research workflows and drug development decision making and assessment in real time - things that would otherwise take months or longer. On April 30th, we are inviting the world to see it operate — live, unrehearsed, and without restriction."

— Panna Sharma, President and Chief Executive Officer, Lantern Pharma Inc.

Webinar Access Details

Date: Thursday, April 30, 2026

Morning Session: 8:30 AM ET

Registration: Register for Morning Session
Afternoon Session: 4:30 PM ET

Registration: Register for Afternoon Session
Subscribe Now: withZeta.ai